Navigation Links
Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute
Date:3/12/2010

WOODCLIFF LAKE, N.J., March 12 /PRNewswire/ -- Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces that it has entered into a licensing agreement with the Johns Hopkins University's Brain Science Institute (Headquarters: Baltimore, Maryland, Director: John Griffin, M.D., "BSI") related to Eisai's GCPII (glutamate carboxypeptidase II) technology.  

Under the terms of the agreement, Eisai has granted BSI non-exclusive U.S. rights to utilize Eisai's GCPII technology to generate GCPII inhibitor molecules for diseases of the central nervous system, including peripheral neuropathy, Alzheimer's disease, stroke, ALS, neurodegeneration and other disorders in humans.  BSI will be responsible for the research and preclinical development activities.  Eisai will have an exclusive option to license molecules generated using the GCPII technology.

"Johns Hopkins brings significant expertise to Eisai's GCPII inhibitor project," said Lynn Kramer, M.D., President, Neuroscience Product Creation Unit at Eisai.  "Our collaboration may lead to a deeper understanding of diseases of the central nervous system and ultimately to the development of innovative new therapies to address unmet medical needs."      

Eisai Inc.

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales).  The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  Headquartered in Woodcliff Lake, New Jersey, the company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com.

*On October 1, 2009, Eisai Research Institute of Boston, Inc. (established in 1987) and Eisai Medical Research Inc. (established in 2002) were merged into Eisai Inc.

SOURCE Eisai Inc.

Back to top

RELATED LINKS
http://www.eisai.com

'/>"/>

SOURCE Eisai Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Inc. and the Alzheimers Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimers Disease
2. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
3. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Diabetics Twice as Likely to Have Hearing Loss; California HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
7. Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
8. Diabetics Twice as Likely to Have Hearing Loss; New Jersey HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
9. Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
10. Diabetics Twice as Likely to Have Hearing Loss; Michigan HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
11. Diabetics Twice as Likely to Have Hearing Loss; Pennsylvania HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... ... large enterprises and telecom service providers, announced today it has been selected by ... enterprise network infrastructure. , “As part of our ongoing commitment to maintain ...
(Date:1/3/2020)... ... January 02, 2020 , ... Fresh from his sold-out Fall ... leading expert and educator in cosmetic and biomimetic dentistry, is expanding his education and ... website at http://www.nejadinstitute.com . , Dentists from around the world attend Dr. Nejad's ...
(Date:1/3/2020)... ... January 03, 2020 , ... Complia Health ... The combined business will offer enterprise solutions for home, residential and community care ... and customer contracts and will move forward under the AlayaCare brand. , Procura ...
Breaking Medicine Technology:
(Date:1/8/2020)... ... 2020 , ... Mirror Mirror Beauty Boutique was ... Memorial Readers’ Choice Awards. Located adjacent to Vitenas Cosmetic Surgery, the office ... reflects Mirror Mirror Beauty Boutique’s commitment to the hottest noninvasive trends that can ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... facility expansion, adding to the company’s 200,000 sq. ft. manufacturing site in College ... of manufacturing space dedicated to POD architectural, mechanical, electrical and automation fit out. ...
(Date:1/7/2020)... ... January 07, 2020 , ... CBD For The People ... keeping the focus on the individual customer service experience. Transparency and integrity are the ... the profits second. By taking care of the people first, they know that satisfied ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... memory impairment, has announced the Best Memory Care Facilities in Lakeland, Florida. The ... features and amenities. , According to the Alzheimer’s Association , 5.6 ...
(Date:1/7/2020)... ... , ... MMJ International Holdings, the premier medical cannabis research company, recently announced ... and CBD proprietary drug formulation which will be used for the treatment of Huntington’s ... confident that it will bring much needed relief to patients suffering from the debilitating ...
Breaking Medicine News(10 mins):